We have all seen the recent headlines: The prices for brand-name prescription drugs—particularly those products deemed as specialty drugs—continue to soar, leading to health insurance plans in the commercial (private market) sector exploring ways to manage these drugs more aggressively. Patients may end up bearing the brunt of these market dynamics, often facing high out-of-pocket (OOP) costs for these drugs.
As the price of expensive medications for a single fill may be thousands of dollars, this represents a significant financial burden for patients, raising concerns around affordability and adherence to a prescribed therapy. To help minimize this financial burden for affected patients, manufacturers of prescription drugs offer financial assistance programs supporting cost-sharing requirements on behalf of qualifying enrollees with commercial insurance.
Xcenda examines the payer tactics to manage copay assistance in a new issue brief.